"The trial is open-label, with the company anticipating being able to report on progress at intervals."
News flow could become far more interesting IMO if trial success emerges..
GK has also stated that IONIC is the most exciting trial in a recent interview. US$45bn projected market, dominated by 2 major players, and NOX has paired up with one of them in what could lead to a clear competitive advantage.
How much is that worth....even on a risk adjusted basis
Ann: Noxopharm IONIC Immuno-Oncology Trial Commences, page-3
Add NOX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
11.0¢ |
Change
0.014(14.6%) |
Mkt cap ! $32.14M | |||
| Open | High | Low | Value | Volume |
| 9.2¢ | 11.5¢ | 9.2¢ | $53.30K | 518.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 48681 | 10.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 11.0¢ | 74195 | 4 |
View Market Depth
| Last trade - 15.45pm 23/08/2024 (20 minute delay) ? |
| NOX (ASX) Chart |